rotation.to
Following this device: dark.
Free account
rotation.to
Appearance
Following this device: dark.
Drag a card by its title · ⚙ to size, swap or remove

The company

Longeveron Inc.

LGVN · Nasdaq

Health CareBiotechnologyNot moving yet

LGVN stood above a rising 150-day average in 7 of the last 52 weekly readings, and has been out of that trend for the last 8 weeks. It is 80.7% below that average now. Biotechnology: 15% of its 561 stocks in an uptrend (−17 points in four weeks); Health Care: 25% (−11 points in four weeks).

Statistics

Rotation
Not moving yet
Weeks in an uptrend
out for 8
Industry in uptrend
15% -17 in 4 wk
Insider buys, 12 months
$0
Insider sales, 12 months
$0
Officials’ trades on record
0
Institutions holding
38 (+9)

In the rotation

Each square a week: lit when it closed above a rising 150-day average. 7 of 52 weeks.

17 Apr – 16 Oct
16%28%39%Apr 26Jun 26Jul 26Sep 26Oct 26

Biotechnology: Few of its stocks are in an uptrend and the share has fallen sharply over four weeks. Health Care: A minority of its stocks are in an uptrend and the share has fallen sharply over four weeks.

Money in and out

1 Nov 2024 – 1 Oct 2026
−$35K$0Nov 24May 25Nov 25Apr 26Oct 26

Open-market buys above the line and sales below, in dollars.

Congress and officials

No member of Congress or official has disclosed a trade in it.

Insiders

Buy orders, 12 months0
Sale orders, 12 months0
Buyers · sellers0 · 0

No open-market buy or sale by its insiders on record.

Lines filed since 2 January 2026, newest first; every insider’s older lines are on their own page.

Institutions

Holders38+9 on the quarter
New · exited13 · 4
Reported value$3.3M

Quarter to 30 Jun 2026, against 31 Mar 2026; newest filing 31 Aug 2026.

ManagerSharesChange
MILLENNIUM MANAGEMENT LLCadded · filed 14 Aug 20261,353,881$952K+907,156+203.1%
Logos Global Management LPnew · filed 14 Aug 20261,287,000$905K+1,287,000
VANGUARD CAPITAL MANAGEMENT LLCadded · filed 13 Aug 2026581,305$409K+39,273+7.2%
BlackRock, Inc.reduced · filed 7 Aug 2026224,170$158K-280.0%
GEODE CAPITAL MANAGEMENT, LLCadded · filed 12 Aug 2026203,761$143K+143+0.1%
JANE STREET GROUP, LLCadded · filed 14 Aug 2026190,370$134K+4,714+2.5%
VANGUARD FIDUCIARY TRUST COadded · filed 13 Aug 2026140,127$99K+101,412+261.9%
Mariner, LLCnew · filed 13 Aug 2026126,000$89K+126,000
ADAR1 Capital Management, LLCreduced · filed 14 Aug 2026108,406$76K-91,594−45.8%
Beacon Pointe Advisors, LLCunchanged · filed 18 Aug 2026100,000$70K00.0%
31 Mar 2024 – 30 Jun 2026
122537Mar 24Sep 24Jun 25Dec 25Jun 26

News

No headline names it lately.

Everyone who traded it

Devin Blass Company insiderCTO & SVP of CMC · last 1 Oct 20260 · 0
Nataliya Agafonova Company insiderChief Medical Officer · last 1 Oct 20260 · 0
Nirav S. Jhaveri Company insiderChief Financial Officer · last 1 Oct 20260 · 0
Paul T. Lehr Company insiderGeneral Counsel, Secretary · last 1 Oct 20261 · 0
Stephen H. Willard Company insiderChief Executive Officer · last 1 Oct 20260 · 0
Arjun J.J. Desai Company insiderDirector · last 19 Aug 20260 · 0
Deborah Ascheim Company insiderDirector · last 19 Aug 20260 · 0
George A. Paletta Jr. Company insiderDirector · last 19 Aug 20260 · 0
Joshua Hare Company insiderChief Scientific Officer · last 19 Aug 20267 · 6
Leah Rush Cann Company insiderDirector · last 19 Aug 20260 · 0
Rock Soffer Company insiderDirector · last 19 Aug 20266 · 6
Roger Joseph Hajjar Company insiderDirector · last 19 Aug 20260 · 0

Same industry

MRNA ModernaLeading+147%
ENTX Entera BioLeading+37%
XNCR XencorLeading+30%

Distance from each stock’s own 150-day average.

Government contracts

No federal award is tied to it.

From its SEC filings

Profit per saleFY 2025 · to 31 Dec 202567.0%
Operating profit marginFY 2024 · to 31 Dec 2024-691%
Free cash flow marginFY 2024 · to 31 Dec 2024-607%
Return on capital employedFY 2024 · to 31 Dec 2024-71.9%
Research spendFY 2024 · to 31 Dec 2024340%
Cash and equivalentsFY 2025 · to 31 Dec 2025$4.7M
Free cash flowFY 2025 · to 31 Dec 2025−$18.9M

Analyst forecasts

No analyst forecasts yet.